Geode Capital Management LLC Buys 434,918 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Geode Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 4.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 9,629,526 shares of the company’s stock after buying an additional 434,918 shares during the quarter. Geode Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $160,248,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after acquiring an additional 11,334,780 shares during the period. Phoenix Financial Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock valued at $632,882,000 after purchasing an additional 9,094,372 shares during the period. Nuveen LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $40,827,000. Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries by 41.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company’s stock valued at $141,555,000 after purchasing an additional 2,462,064 shares during the last quarter. Finally, Ion Asset Management Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after purchasing an additional 2,383,500 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $24.86 on Wednesday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $26.38. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm has a market capitalization of $28.51 billion, a price-to-earnings ratio of -155.38, a PEG ratio of 1.11 and a beta of 0.70. The stock’s 50-day simple moving average is $20.60 and its 200-day simple moving average is $18.37.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the business earned $0.69 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 3.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on TEVA shares. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average price target of $25.86.

Insider Activity

In related news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.49% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.